Literature DB >> 25838371

Vaccine testing. Ebola and beyond.

Marc Lipsitch1, Nir Eyal2, M Elizabeth Halloran3, Miguel A Hernán4, Ira M Longini5, Eli N Perencevich6, Rebecca F Grais7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25838371      PMCID： PMC4408019          DOI： 10.1126/science.aaa3178

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  6 in total

1.  A "politically robust" experimental design for public policy evaluation, with application to the Mexican universal health insurance program.

Authors:  Gary King; Emmanuela Gakidou; Nirmala Ravishankar; Ryan T Moore; Jason Lakin; Manett Vargas; Martha Maria Tellez-Rojo; Juan Eugenio Hernandez Avila; Mauricio Hernandez Avila; Hector Hernandez Llamas
Journal:  J Policy Anal Manage       Date:  2007

2.  Public policy for the poor? A randomised assessment of the Mexican universal health insurance programme.

Authors:  Gary King; Emmanuela Gakidou; Kosuke Imai; Jason Lakin; Ryan T Moore; Clayton Nall; Nirmala Ravishankar; Manett Vargas; Martha María Téllez-Rojo; Juan Eugenio Hernández Avila; Mauricio Hernández Avila; Héctor Hernández Llamas
Journal:  Lancet       Date:  2009-04-07       Impact factor: 79.321

3.  Properties of permuted-block randomization in clinical trials.

Authors:  J P Matts; J M Lachin
Journal:  Control Clin Trials       Date:  1988-12

4.  Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial.

Authors:  Collins C Iwuji; Joanna Orne-Gliemann; Frank Tanser; Sylvie Boyer; Richard J Lessells; France Lert; John Imrie; Till Bärnighausen; Claire Rekacewicz; Brigitte Bazin; Marie-Louise Newell; François Dabis
Journal:  Trials       Date:  2013-07-23       Impact factor: 2.279

5.  The race against time.

Authors:  Fiona Fleck; Ana Lesher
Journal:  Bull World Health Organ       Date:  2015-01-01       Impact factor: 9.408

6.  Randomised controlled trials for Ebola: practical and ethical issues.

Authors:  Clement Adebamowo; Oumou Bah-Sow; Fred Binka; Roberto Bruzzone; Arthur Caplan; Jean-François Delfraissy; David Heymann; Peter Horby; Pontiano Kaleebu; Jean-Jacques Muyembe Tamfum; Piero Olliaro; Peter Piot; Abdul Tejan-Cole; Oyewale Tomori; Aissatou Toure; Els Torreele; John Whitehead
Journal:  Lancet       Date:  2014-10-13       Impact factor: 79.321
  6 in total
  9 in total

Review 1.  Improving vaccine trials in infectious disease emergencies.

Authors:  Marc Lipsitch; Nir Eyal
Journal:  Science       Date:  2017-07-14       Impact factor: 47.728

2.  Statistical Properties of Stepped Wedge Cluster-Randomized Trials in Infectious Disease Outbreaks.

Authors:  Lee Kennedy-Shaffer; Marc Lipsitch
Journal:  Am J Epidemiol       Date:  2020-11-02       Impact factor: 4.897

3.  Leveraging contact network structure in the design of cluster randomized trials.

Authors:  Guy Harling; Rui Wang; Jukka-Pekka Onnela; Victor De Gruttola
Journal:  Clin Trials       Date:  2016-10-24       Impact factor: 2.486

4.  Vaccine testing for emerging infections: the case for individual randomisation.

Authors:  Nir Eyal; Marc Lipsitch
Journal:  J Med Ethics       Date:  2017-04-10       Impact factor: 2.903

5.  Ethical Rationale for the Ebola "Ring Vaccination" Trial Design.

Authors:  Annette Rid; Franklin G Miller
Journal:  Am J Public Health       Date:  2016-01-21       Impact factor: 9.308

6.  Ebola vaccine development plan: ethics, concerns and proposed measures.

Authors:  Morenike Oluwatoyin Folayan; Aminu Yakubu; Bridget Haire; Kristin Peterson
Journal:  BMC Med Ethics       Date:  2016-02-08       Impact factor: 2.652

7.  The Ebola Outbreak of 2014-2015: From Coordinated Multilateral Action to Effective Disease Containment, Vaccine Development, and Beyond.

Authors:  Thomas R Wojda; Pamela L Valenza; Kristine Cornejo; Thomas McGinley; Sagar C Galwankar; Dhanashree Kelkar; Richard P Sharpe; Thomas J Papadimos; Stanislaw P Stawicki
Journal:  J Glob Infect Dis       Date:  2015 Oct-Dec

8.  Choices in vaccine trial design in epidemics of emerging infections.

Authors:  Rebecca Kahn; Annette Rid; Peter G Smith; Nir Eyal; Marc Lipsitch
Journal:  PLoS Med       Date:  2018-08-07       Impact factor: 11.069

9.  Why Challenge Trials of SARS-CoV-2 Vaccines Could Be Ethical Despite Risk of Severe Adverse Events.

Authors:  Nir Eyal
Journal:  Ethics Hum Res       Date:  2020-05-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.